Borderline personality disorder

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Brain Canada launches Season 3 of Playing with Marbles podcast – inside youth mental health

Retrieved on: 
Monday, February 26, 2024
Anxiety, Mental health, Dissociative identity disorder, Borderline personality disorder, Marble (toy), Attention deficit hyperactivity disorder, Eating disorder, ADHD, OCD, Travel, Depression, Nursing

MONTREAL, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Playing with Marbles, Brain Canada’s English-language podcast on everything brain, is back.

Key Points: 
  • MONTREAL, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Playing with Marbles, Brain Canada’s English-language podcast on everything brain, is back.
  • This season we’re zeroing in on the perspectives of people with lived experience of different mental health conditions.
  • Half of Canadians will have experienced a mental illness by the age of 40, and young people are especially vulnerable to mental illness.
  • “One in four young people need to access mental health services every year,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024
Vall d'Hebron University Hospital, Teaching hospital, Borderline personality disorder, Yale school, BPD, Yale School of Medicine, MD, Vall, Genomics, Webcast, Doctor of Philosophy, KOL, Phase

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Retrieved on: 
Friday, January 5, 2024
Phase, LSD1, Identity disturbance, NMDR, Agitation, Depression, FDA, CMO, Conference call, Journal, Conference, Disease, Aggression, Emptiness, Knowledge, Schizophrenia, Overalls, Safety, Deficit spending, Steven Spielberg filmography, Aes, GST, Genomics, Anxiety, CNS, Gene, Biomarker, Webcast, Suicidal ideation, Patient, Memory, BEST, Borderline personality disorder, BPD, Observation, Paranoia, Medical imaging

MADRID, Spain and BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced topline results from the Phase IIb PORTICO trial, evaluating the efficacy and safety of vafidemstat in Borderline Personality Disorder (BPD).

Key Points: 
  • ORYZON will host a conference call and webcast on January 7, 2024 at 5:30 pm Pacific Time to discuss PORTICO Phase IIb results.
  • However, statistically significant overall disease improvement was achieved on the secondary endpoint Borderline Evaluation of Severity (BEST) across weeks 8-12 (p = 0.042).
  • It was also encouraging to note that all results favored vafidemstat treatment over placebo across the multiple independent primary and secondary efficacy endpoints.
  • An important aim of PORTICO was to learn what potential endpoints would be important to leverage in a future Phase III registrational trial.

ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million

Retrieved on: 
Tuesday, November 21, 2023
Note, Borderline personality disorder, Genomics, VWAP, Pharmaceutical industry

The financing program consists of several tranches of up to €5 million each to be drawn at the discretion of Oryzon, subject to customary conditions and to the progress of the ongoing clinical trials and the liquidity of the Oryzon share.

Key Points: 
  • The financing program consists of several tranches of up to €5 million each to be drawn at the discretion of Oryzon, subject to customary conditions and to the progress of the ongoing clinical trials and the liquidity of the Oryzon share.
  • The Convertible Notes (CN) have a maturity of 48 months, zero interest rate, and have no warrants associated.
  • Oryzon has the right to execute the redemption of any or all Notes at a premium of 3%.
  • As a responsible and loyal financial partner, Nice & Green will remain attentive to the evolving financing needs of Oryzon in the near and long term.”

New Study Reveals a Staggering 40% of ADHD-Diagnosed Individuals Also Struggle with Anxiety

Retrieved on: 
Tuesday, December 12, 2023
Attention deficit hyperactivity disorder, Research, Prevalence, Substance abuse, Clutch (eggs), Anxiety, OCD, DSM-IV codes, Multimedia, ADHD, Borderline personality disorder, Bipolar disorder, Partnership, PTSD, Insomnia, Psychiatry, Dyslexia, Spectrum, Obsessive–compulsive disorder, Dietary supplement

LONDON, Dec. 12, 2023 /PRNewswire-PRWeb/ -- A ground-breaking study conducted in partnership with the ADHDtest website and supervised by MD Adeel Sarwar has brought to light a significant correlation between ADHD (Attention-Deficit/Hyperactivity Disorder) and psychiatric comorbidities. Among the most startling of these findings is that a whopping 40.40% of individuals diagnosed with ADHD also show symptoms of anxiety.

Key Points: 
  • Among the most startling of these findings is that a whopping 40.40% of individuals diagnosed with ADHD also show symptoms of anxiety.
  • The comprehensive study meticulously analyzed a diverse cohort of 1,528 participants to determine the prevalence of ADHD and its associated conditions.
  • This study highlights the significant overlap between ADHD and anxiety disorders considering ADHD has been linked with numerous psychiatric disorders.
  • Beyond the staggering correlation with anxiety, the study illuminated a myriad of psychiatric comorbidities associated with ADHD.

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Retrieved on: 
Tuesday, November 7, 2023
ORY, Genomics, Aggression, DMC, ISIN, CNS, Data monitoring committee, EudraCT, Disease, ECNP, Safety, Agitation, BPD, Interim analysis, Patient, Borderline personality disorder, Pharmaceutical industry, Medical device

: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial evaluating the efficacy and safety of vafidemstat in a BPD population.

Key Points: 
  • : 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial evaluating the efficacy and safety of vafidemstat in a BPD population.
  • The trial has two primary endpoints: reduction of agitation and aggression and overall disease improvement in BPD severity.
  • The independent Data Monitoring Committee (DMC) has met routinely and reviewed unblinded safety data throughout the PORTICO trial.
  • Our quest on the primary endpoints is replicated in a rich set of secondary endpoints, making PORTICO a very informative trial.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

Brain & Behavior Research Foundation Awards $10.2 Million in Young Investigator Grants to 150 Mental Health Scientists

Retrieved on: 
Thursday, October 19, 2023
Brain & Behavior Research Foundation, Spectrum, Psychiatry, Psychosis, TFU, Prevalence, Pathology, Bipolar disorder, Research, Brain, OCD, PTSD, Psilocybin, Borderline personality disorder, Schizophrenia, Eating, M.D, Depression, Anxiety, Presidential Young Investigator Award, DSM-IV codes, ADHD, B cell, Pharmaceutical industry, Medical imaging, Young

A third grantee will study the application of transcranial focused ultrasound (tFUS) in such illnesses as PTSD, anxiety, and OCD.

Key Points: 
  • A third grantee will study the application of transcranial focused ultrasound (tFUS) in such illnesses as PTSD, anxiety, and OCD.
  • “BBRF Young Investigators represent a new generation of researchers who are pioneering breakthroughs in mental health research.
  • They are at the cutting edge of progress in brain and psychiatric research,” said Jeffrey Borenstein, M.D, President & CEO of the Brain & Behavior Research Foundation.
  • “BBRF Young Investigator grants have led to groundbreaking research that has improved the lives of people living with mental illness,” said Herbert Pardes, M.D., President of the BBRF Scientific Council.

Advocacy Organizations Applaud Governor Newsom on Signing AB1412 to Eliminate Borderline Personality Disorder Stigma

Retrieved on: 
Thursday, October 19, 2023
Emotional dysregulation, Suicide, Education, Public policy, Wisconsin's 37th Assembly district, Self-harm, Emotion, Organization, CBHA, Hart, Research, Quality of life, World Mental Health Day, 2022 California's 17th State Assembly district special election, Borderline personality disorder, BPD, Recidivism, Nursing

This represents a victory for BPD clients and advocacy organizations including the bill's sponsor, California Council of Community Behavioral Health Agencies (CBHA), Emotions Matter, and the National Education Alliance for Borderline Personality Disorder.

Key Points: 
  • This represents a victory for BPD clients and advocacy organizations including the bill's sponsor, California Council of Community Behavioral Health Agencies (CBHA), Emotions Matter, and the National Education Alliance for Borderline Personality Disorder.
  • Approximately 1.6% of the U. S. population is affected by borderline personality disorder (BPD), a highly stigmatized mental illness characterized by emotional dysregulation, self-harm and suicidality.
  • "Passing AB1412 demonstrates the power of grassroots advocacy to engage in legislative efforts to increase BPD education," commented Abby Ingber, Executive Director of the National Education Alliance for Borderline Personality Disorder.
  • The National Education Alliance for Borderline Personality Disorder is a 501c3 non-profit organization to provide education, decrease stigma, promote research, and enhance the quality of life of those affected by BPD.